FGEN -
FibroGen, Inc
| Day |
1m |
10m |
60m |
PreMarket |
Market |
AfterHours |
Gap |
| 8.31 0.15 (1.82%) |
--- |
--- |
-0.09 (-1.04%) |
--- |
0.15 (1.82%) |
--- |
--- |
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
Earnings & Ratios
- Basic EPS:
- -1.88
- Diluted EPS:
- -1.88
- Basic P/E:
- -4.5005
- Diluted P/E:
- -4.5005
- RSI(14) 1m:
- 17.75
- VWAP:
- 8.46
- RVol:
Events
| Period |
Kind |
Movement |
Occurred At |
Related News
FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation
Aug 18, 2025 11:00
Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million
Feb 20, 2025 18:08
Liver Fibrosis Market Is Expected to Reach USD 43.98 Billion By 2030
Sep 02, 2024 20:15
Catalyst Accelerator Ogden Selects 11 Companies for Fall 2024 Cohort in Partnership with the Department of the Air Force Digital Transformation Office
Aug 23, 2024 22:04
FibroGen Stock Is Surging After The Bell: What's Going On?
Jun 03, 2024 20:48
FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials
Jun 03, 2024 20:05
FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors
Jun 03, 2024 20:02
FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting
May 23, 2024 21:05
FibroGen Reports First Quarter 2024 Financial Results
May 06, 2024 20:02
Zoetis (ZTS) Beats Q1 Earnings and Revenue Estimates
May 02, 2024 12:10